Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis
-
Published:2019-04
Issue:2
Volume:17
Page:e383-e386
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
van Nuland MerelORCID,
Groenland Steffie,
Bergman Andre M.,
Rotmans Joris I.,
Rosing Hilde,
Beijnen Jos H.,
Huitema Alwin D.R.
Reference10 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study;Allen;JAMA Oncol,2017
2. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016
3. Global Cancer Facts and Figures,2015
4. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer;Heidenreich;Eur Urol,2014
5. Clinical pharmacokinetic studies of enzalutamide;Gibbons;Clin Pharmacokinet,2015
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献